Evaluation of a proposed determinative method to determine concentrations of the AQUI-SŪ marker residue in fillet tissue from coolwater and warmwater fish species The work described in this protocol will be conducted as a regulated study. The data will be submitted to the Center for Veterinary Medicine (CVM) to support acceptance of the described method as a determinative method. The work described in this protocol assumes that isoeugenol will be selected as the marker residue for AQUI-SŪ. A tolerance concentration for the AQUI-SŪ marker residue has not been established, but is projected to be >1 ug/g and <100 ug/g. There is a critical need in U.S. public aquaculture and fisheries management for an anesthetic with zero withdrawal time. Such an anesthetic would have applications for nearly all fish species. For field studies, including population estimates and age and growth studies conducted by federal and state conservation agencies, fish could be handled with minimal stress and released immediately. A zero withdrawal time anesthetic would increase the effectiveness of stocking programs by decreasing stress related mortalities that occur during and after transport of fish. The availability of an anesthetic with no withdrawal time would also allow human consumption of spawned fish, such as Pacific salmon, immediately after exposure. Currently, Finquel (tricane methanesulphonate or MS-222) is the only fish anesthetic approved by the U.S. Food and Drug Administration (FDA). Use of this anesthetic to collect field data, spawn fish, or sedate fish during transport is constrained by a 21-day withdrawal period. The approval of AQUI-SŪ as a fish anesthetic with a zero withdrawal time is being pursued in the U.S. As part of the approval process, a marker residue for AQUI- SŪ must be selected from AQUI-SŪ residues extracted from edible fillet tissue from exposed fish. After selection of the marker residue, a determinative method for the marker residue must be developed and validated in a variety of fish species from the colwater, coolwater, and warmwater temperature groups according to FDA guidelines. Thereafter, AQUI-STM marker residue depletion studies can be conducted. Recently, a total residue depletion study was conducted at the Upper Midwest Environmental Sciences Center (UMESC). Data from the study indicated that isoeugenol was the primary residue in extracts from rainbow trout (Oncorhynchus mykiss) skin-on fillet tissue after exposure. Since isoeugenol was the primary residue in rainbow trout fillet tissue, we will assume isoeugenol will be selected as the marker residue for AQUI- SŪ. Assuming isoeugenol is selected as the marker residue, a tolerance concentration for isoeugenol will eventually be declared by the Center for Veterinary Medicine (CVM) after all mammalian toxicology tests are completed and evaluated. Teratogenicity and carcinogenicity tests with isoeugenol have been conducted by the National Toxicology Program (NTP). Data from those tests are undergoing review by NTP. Based on current information, a tolerance concentration for the AQUI-SŪ marker residue will not be established until 2006. Despite the lack of a tolerance concentration for the AQUI-SŪ marker residue, we will conduct work that will address data requirements for a proposed AQUI-SŪ marker residue determinative method. A method was developed at the UMESC to determine isoeugenol concentrations in fillet tissue from rainbow trout, a coldwater fish species. The method must be evaluated with fillet tissue from coolwater and warmwater fish species before it can be considered as the determinative method for the AQUI-SŪ marker residue. This study will evaluate the method with guidance described in CVM guideline 3, “General principles for evaluating the safety of compounds used in food-producing animals”, section IV, “Guideline for approval of a method of analysis for residues”. The isoeugenol concentrations chosen for investigation include a relatively wide range of concentrations and were chosen by incorporating current knowledge of isoeugenol concentrations in rainbow trout fillet tissue after exposing fish to AQUI-SŪ. Objectives The following objectives were established to support a determinative method for isoeugenol in edible fillet tissue from coolwater and warmwater fish species: (1) evaluate method interferences from naturally endogenous compounds extracted from control fillet tissue from coolwater and warmwater fish species; (2) evaluate method systematic error by assessing percent recovery with fillet tissue from coolwater and warmwater fish species fortified with isoeugenol at 1, 50, and 100 ug/g; (3) evaluate method repeatability by assessing within-day and day-to-day precision with fillet tissue from coolwater and warmwater fish species fortified with isoeugenol at 1, 50, and 100 ug/g; (4) evaluate method repeatability with biologically incurred isoeugenol residues in fillet tissue from coolwater and warmwater fish species; (5) evaluate method detection and quantitation limits with fillet tissue from coolwater and warmwater fish species; (6) evaluate the stability of isoeugenol in fillet tissue extracts fillet tissue from coolwater and warmwater fish species; and (7) evaluate the stability of isoeugenol in fillet tissue fillet tissue from coolwater and warmwater fish species containing biologically incurred isoeugenol residues. Branch of Chemistry and Physiology – FY-05 Productivity Inventory Page of 4 Branch of Chemistry and Physiology – FY-05 Productivity Inventory Page of 2